A

Amgen

Makes biotech medicines for serious illnesses

Engineering Cost Analytics - Source to Pay Support

Full-TimeUpdated on 10/24/2026
No salary listed
Senior, Expert
Bachelor's, Master's
Hyderabad, Telangana, India
In PersonOn-site in Hyderabad, India.
Operations & LogisticsProcurement & Sourcing

About the job

Requirements
  • A Bachelor's or Master's degree in Engineering, Finance, Project Management, or a related field.
  • Five to nine years of experience in project controls, cost management, engineering, finance, procurement, capital projects, or a related field.
  • A strong understanding of Source-to-Pay processes, including purchase requisitions, purchase orders, invoices, approvals, issue resolution, and payment-related workflows.
  • Experience working with Ariba, SAP, or similar procurement or finance systems.
  • Experience supporting project controls, engineering, capital projects, procurement, finance, or related project delivery functions.
  • Ability to track issues, monitor performance, improve process discipline, and drive timely resolution.
  • A strong understanding of process compliance, documentation discipline, approval controls, and audit readiness within Source-to-Pay or finance-related workflows.
  • Ability to partner effectively with Procurement, Finance, Source-to-Pay, Engineering, vendors, and project teams.
  • Organization, coordination, and follow-through skills.
  • Communication and stakeholder management skills across global teams.
  • Ability to collaborate across global teams, cultures, and time zones.
  • Attention to detail and accountability for compliance and accuracy.
  • Problem-solving ability, including escalating and resolving issues effectively.
  • Flexibility to work across different shifts as business needs require.
Responsibilities
  • Provide cost analytics support for global capital projects.
  • Execute daily Source-to-Pay activities, coordinate workloads, review quality, and resolve issues for global capital projects.
  • Coordinate purchase requisitions and purchase orders, including required inputs, documentation, follow-up, and process completion.
  • Review and validate invoices, route approvals, and resolve issues in alignment with project, Finance, and Source-to-Pay requirements.
  • Support dashboards and reporting using tools such as Power BI, SAP, and data platforms.
  • Perform benchmark analytics for global capital projects.
  • Partner with Procurement and Finance to align processes, resolve issues, and improve handoffs.
  • Coordinate with vendors as needed to resolve invoice, purchase order, documentation, or payment-related questions.
  • Maintain standard work, process documentation, trackers, and escalation routines for Source-to-Pay activities.
  • Maintain compliance with established Source-to-Pay and project controls processes by ensuring required documentation, approvals, and process evidence are complete and audit ready.
  • Support workstream metrics and cycle-time expectations to improve timeliness, quality, issue resolution, and stakeholder satisfaction.
  • Drive continuous improvement and cycle-time reduction across Source-to-Pay workflows, including requisition, purchase order, invoice, and payment-related processes.
Desired Qualifications
  • Experience in the global pharmaceutical industry.
  • Experience supporting capital projects in pharmaceutical, biotechnology, life sciences, or other regulated industries.
  • Experience working in a centralized service model or global capability centre.
  • Familiarity with process improvement, cycle-time reduction, service delivery metrics, or operational excellence.
  • Experience developing trackers, process documentation, standard operating procedures, dashboards, or standard work instructions.
  • Familiarity with Power BI, reporting tools, or project controls analytics.
  • A relevant certification in project management, procurement, supply chain, finance, process improvement, or a related discipline is recommended.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.